PDFF Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==Recent Meetings/Call Summaries== | ==Recent Meetings/Call Summaries== | ||
*[[Media:2017_09-07_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|09.07.2017 QIBA PDFF Biomarker Ctte Call Summary]] | |||
*[[Media:2017_08-03_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|08.03.2017 QIBA PDFF Biomarker Ctte Call Summary]] | |||
*[[Media:2017_07-06_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|07.06.2017 QIBA PDFF Biomarker Ctte Call Summary]] | |||
*[[PDFF Biomarker Committee Call Summaries]] | *[[PDFF Biomarker Committee Call Summaries]] | ||
Revision as of 15:15, 3 November 2017
- Co-chairs: Scott Reeder, MD, PhD, Takeshi Yokoo, MD, PhD
- Secretary: Susan Weinmann
The PDFF Biomarker Committee seeks to develop a quantitative Profile for PDFF.
Recent Meetings/Call Summaries
- 09.07.2017 QIBA PDFF Biomarker Ctte Call Summary
- 08.03.2017 QIBA PDFF Biomarker Ctte Call Summary
- 07.06.2017 QIBA PDFF Biomarker Ctte Call Summary